Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas

NCT01900158 is registered in ClinicalTrials.gov with PCI Biotech AS as lead sponsor.

NCT NCT01900158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01900158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas
Lead sponsor
PCI Biotech AS
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2013
Completion date
February 28, 2019
Enrollment
24 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma